Healthpeak Properties Analyst Price Targets

Wall Street analyst price targets and consensus rating for Healthpeak Properties (DOC).

Price Target Range — 13 Quarters

Analyst Consensus — 19 Analysts

7Buy

12Hold

Consensus RatingOutperform# Analysts19Avg. Consensus PT$21Upside to Avg. PT+12.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 13, 2026	UBS	—	PT Cut	Neutral	$22→$20
Oct 13, 2026	Barclays	Richard Hightower	PT Cut	Equal-Weight	$24→$21
Sep 21, 2026	Evercore ISI Group	James Kammert	PT Cut	In-Line	$23→$22
Sep 15, 2026	Jefferies	Joe Dickstein	Assumes	Hold	$22→$21
Aug 31, 2026	Barclays	Richard Hightower	PT Raise	Equal-Weight	$23→$24
Aug 13, 2026	Baird	Amanda Sweitzer	PT Raise	Outperform	$21→$24
Aug 11, 2026	Citigroup	Nick Joseph	PT Raise	Neutral	$20→$22
Aug 10, 2026	RBC Capital	Michael Carroll	PT Raise	Outperform	$21→$24
Aug 6, 2026	Cantor Fitzgerald	Richard Anderson	PT Raise	Neutral	$20→$23
Jul 15, 2026	Wells Fargo	John Kilichowski	PT Raise	Equal-Weight	$20→$22
Jul 8, 2026	UBS	—	PT Raise	Neutral	$19→$22
Jul 7, 2026	Barclays	Richard Hightower	Initiate	Overweight→Equal-Weight	$23
Jul 6, 2026	Mizuho	Vikram Malhotra	PT Raise	Outperform	$21→$24
Jun 24, 2026	JP Morgan	Michael Mueller	PT Raise	Neutral	$18→$21
Jun 17, 2026	Raymond James	David Rodgers	Reinstates	Outperform→Market Perform	—
Jun 15, 2026	BMO Capital	Juan Sanabria	PT Raise	Outperform	$20→$24
Jun 11, 2026	Morgan Stanley	Richard Hill	Downgrade	Overweight→Equal-Weight	$20→$22
Jun 1, 2026	Wells Fargo	John Kilichowski	PT Raise	Equal-Weight	$18→$20
May 27, 2026	Scotiabank	Nicholas Yulico	PT Raise	Sector Perform	$19→$21
May 22, 2026	Morgan Stanley	Richard Hill	PT Raise	Overweight	$18→$20

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Maintains Neutral on Healthpeak Properties, Lowers Price Target to $20

UBS maintains Healthpeak Properties (NYSE:DOC) with a Neutral and lowers the price target from $21.5 to $20.

Benzinga Newsdesk

PRO
Barclays Maintains Equal-Weight on Healthpeak Properties, Lowers Price Target to $21

Barclays analyst Richard Hightower maintains Healthpeak Properties (NYSE:DOC) with a Equal-Weight and lowers the price target from $24 to $21.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains In-Line on Healthpeak Properties, Lowers Price Target to $22

Evercore ISI Group analyst James Kammert maintains Healthpeak Properties (NYSE:DOC) with a In-Line and lowers the price target from $23 to $22.

Benzinga Newsdesk

PRO
Jefferies Assumes Healthpeak Properties at Hold, Lowers Price Target of $21

Jefferies analyst Joe Dickstein assumes Healthpeak Properties (NYSE:DOC) with a Hold rating and lowers Price Target of $21.

Benzinga Newsdesk

PRO
Barclays Maintains Equal-Weight on Healthpeak Properties, Raises Price Target to $24

Barclays analyst Richard Hightower maintains Healthpeak Properties (NYSE:DOC) with a Equal-Weight and raises the price target from $23 to $24.

Benzinga Newsdesk

Wall Street's Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields

In uncertain markets, investors turn to dividend-yielding stocks. Benzinga provides latest analyst ratings & news for high-yielding stocks.

Avi Kapoor

Healthpeak Properties Inc

Healthpeak Properties Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
UBS Maintains Neutral on Healthpeak Properties, Lowers Price Target to $20

PRO
Barclays Maintains Equal-Weight on Healthpeak Properties, Lowers Price Target to $21

PRO
Evercore ISI Group Maintains In-Line on Healthpeak Properties, Lowers Price Target to $22

PRO
Jefferies Assumes Healthpeak Properties at Hold, Lowers Price Target of $21

PRO
Barclays Maintains Equal-Weight on Healthpeak Properties, Raises Price Target to $24

Wall Street's Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields

People Also Watch

People Also Watch

Healthpeak Properties Inc

Healthpeak Properties Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROUBS Maintains Neutral on Healthpeak Properties, Lowers Price Target to $20

PROBarclays Maintains Equal-Weight on Healthpeak Properties, Lowers Price Target to $21

PROEvercore ISI Group Maintains In-Line on Healthpeak Properties, Lowers Price Target to $22

PROJefferies Assumes Healthpeak Properties at Hold, Lowers Price Target of $21

PROBarclays Maintains Equal-Weight on Healthpeak Properties, Raises Price Target to $24

Wall Street's Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields

People Also Watch

People Also Watch

PRO
UBS Maintains Neutral on Healthpeak Properties, Lowers Price Target to $20

PRO
Barclays Maintains Equal-Weight on Healthpeak Properties, Lowers Price Target to $21

PRO
Evercore ISI Group Maintains In-Line on Healthpeak Properties, Lowers Price Target to $22

PRO
Jefferies Assumes Healthpeak Properties at Hold, Lowers Price Target of $21

PRO
Barclays Maintains Equal-Weight on Healthpeak Properties, Raises Price Target to $24